gut.bmj1d
Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies
Objective We performed a meta-analysis of observational studies to quantify the magnitude of the association between non-alcoholic fatty liver disease (NAFLD) and risk of extrahepatic cancers. Design ...
gut.bmj2d
Small metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease
Correspondence to Professor Bernd Schnabl, Department of Medicine, University of California, San Diego, CA 92093, USA; beschnabl{at}ucsd.edu The spectrum of non-alcoholic fatty liver disease (NAFLD) ...
gut.bmj7d
Targeting the gut-liver-immune axis to treat cirrhosis
Cirrhotic portal hypertension is characterised by development of the decompensating events of ascites, encephalopathy, portal hypertensive bleeding and hepatorenal syndrome, which arise in a setting ...
gut.bmj3d
Definition and taxonomy of interval colorectal cancers: a proposal for standardising nomenclature
1 Division of Gastroenterology and Hepatology, Department of Internal Medicine; and GROW, School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht The ...
gut.bmj5d
Risk of acute arterial events associated with treatment of inflammatory bowel diseases: nationwide French cohort study
Correspondence to Julien Kirchgesner, Service de Gastroentérologie et Nutrition, Hôpital Saint-Antoine, Assistance Publique - Hôpitaux de Paris, 184 rue du faubourg Saint-Antoine, Paris 75012, France; ...
gut.bmj4d
Global incidence of oesophageal cancer by histological subtype in 2012
Correspondence to Dr Melina Arnold, Section of Cancer Surveillance, International Agency for Research on Cancer, 150 Cours Albert Thomas, Lyon 69008, France; arnoldm{at}fellows.iarc.fr Objective The ...
gut.bmj7d
Is gastric cancer becoming a rare disease? A global assessment of predicted incidence trends to 2035
Objectives The incidence of gastric cancer continues to decrease globally, approaching levels that in some populations could define it as a rare disease. To explore this on a wider scale, we predict ...
gut.bmj2d
Australian consensus statements for the regulation, production and use of faecal microbiota transplantation in clinical practice
Objective Faecal microbiota transplantation (FMT) has proved to be an extremely effective treatment for recurrent Clostridioides difficile infection, and there is interest in its potential application ...
gut.bmj8d
Faecal metabolome and its determinants in inflammatory bowel disease
Objective Inflammatory bowel disease (IBD) is a multifactorial immune-mediated inflammatory disease of the intestine, comprising Crohn’s disease and ulcerative colitis. By characterising metabolites ...
gut.bmj6d
Alternative treatments for type 2 diabetes and associated metabolic diseases: medical therapy or endoscopic duodenal mucosal remodelling?
Correspondence to Professor Jacques J G H M Bergman, Gastroenterology and Hepatology, Amsterdam UMC Location AMC, Amsterdam 1105 AZ, The Netherlands; j.j.bergman{at}amsterdamumc.nl Despite important ...
gut.bmj4d
Maternal antibiotic exposure during pregnancy and risk of IBD in offspring: a population-based cohort study
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be ...
gut.bmj8d
Nerve growth factor and Trk high affinity receptor (TrkA) gene expression in inflammatory bowel disease
Dr Helmut Friess, Department of Visceral and Transplantation Surgery, University of Bern, Inselspital, CH-3010 Bern, Switzerland. Email: helmut.friess{at}insel.ch BACKGROUND Nerve growth factor (NGF), ...